Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI105820

The nonerythropoietic component of early bilirubin

M. Levitt, B. A. Schacter, A. Zipursky, and L. G. Israels

Department of Medicine, University of Manitoba and the Manitoba Cancer Treatment and Research Foundation, Winnipeg 3, Canada

Department of Pediatrics, University of Manitoba and the Manitoba Cancer Treatment and Research Foundation, Winnipeg 3, Canada

Find articles by Levitt, M. in: JCI | PubMed | Google Scholar

Department of Medicine, University of Manitoba and the Manitoba Cancer Treatment and Research Foundation, Winnipeg 3, Canada

Department of Pediatrics, University of Manitoba and the Manitoba Cancer Treatment and Research Foundation, Winnipeg 3, Canada

Find articles by Schacter, B. in: JCI | PubMed | Google Scholar

Department of Medicine, University of Manitoba and the Manitoba Cancer Treatment and Research Foundation, Winnipeg 3, Canada

Department of Pediatrics, University of Manitoba and the Manitoba Cancer Treatment and Research Foundation, Winnipeg 3, Canada

Find articles by Zipursky, A. in: JCI | PubMed | Google Scholar

Department of Medicine, University of Manitoba and the Manitoba Cancer Treatment and Research Foundation, Winnipeg 3, Canada

Department of Pediatrics, University of Manitoba and the Manitoba Cancer Treatment and Research Foundation, Winnipeg 3, Canada

Find articles by Israels, L. in: JCI | PubMed | Google Scholar

Published June 1, 1968 - More info

Published in Volume 47, Issue 6 on June 1, 1968
J Clin Invest. 1968;47(6):1281–1294. https://doi.org/10.1172/JCI105820.
© 1968 The American Society for Clinical Investigation
Published June 1, 1968 - Version history
View PDF
Abstract

The early labeled bilirubin consists of two primary components. The more rapidly synthesized of the two is independent of erythropoiesis (nonerythropoietic), whereas the second fraction is related to red cell production (erythyropoietic). The present studies concern the origin of the nonerythropoietic component.

The nonerythropoietic, early labeled bilirubin was studied in bile fistula rats with (delta ALA)-4-14C delta aminolevulinic acid and glycine-2-14C as precursors. That nephrectomy did not reduce the size of this component despite the large and rapidly turning over pool of renal heme suggests that this pool may be of minor importance in its production. Intoxication with lead to a level that reduced hepatic heme synthesis was associated with a decrease in early bilirubin formation. The synthesis of this bilirubin was assessed in animals with phenobarbital-induced heme protein and cycloheximide-suppressed protein synthesis. Rats pretreated with phenobarbital at a dose level of 60 mg/kg with induction of cytochrome P-450 synthesis showed a minor increase in early labeling when glycine-2-14C but not when delta ALA-4-14C was used as precursor. Rats given cycloheximide at a dose level that markedly reduced hepatic protein and cytochrome P-450 synthesis but allowed heme synthesis to continue at 60% of its pretreatment level synthesized normal or increased amounts of early bilirubin from delta ALA-4-14C. Allylisopropylacetamide intoxication caused little change in early bilirubin formation, whereas aminotriazole given at a time after maximal hepatic heme labeling produced a small but significant increase in the appearance of labeled bilirubin.

These findings indicate that early bilirubin production is little influenced by increased hepatic porphyrin synthesis or by changes in the rapidly turning over heme protein P-450. A minimal increase attends catalase inactivation by aminotriazole. Normal or increased synthesis takes place in the presence of suppression of protein synthesis. This finding suggests that the nonerythropoietic early bilirubin may itself consist of two subcomponents. The first of these may arise from free tissue heme or its precursors, and the second may derive from the turnover of the heme proteins. The first subcomponent may serve as a regulatory mechanism for the removal of heme synthesized in excess of its protein acceptor. A composite scheme is proposed for the origin of the total early bilirubin from heme compartments in tissue and marrow.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1281
page 1281
icon of scanned page 1282
page 1282
icon of scanned page 1283
page 1283
icon of scanned page 1284
page 1284
icon of scanned page 1285
page 1285
icon of scanned page 1286
page 1286
icon of scanned page 1287
page 1287
icon of scanned page 1288
page 1288
icon of scanned page 1289
page 1289
icon of scanned page 1290
page 1290
icon of scanned page 1291
page 1291
icon of scanned page 1292
page 1292
icon of scanned page 1293
page 1293
icon of scanned page 1294
page 1294
Version history
  • Version 1 (June 1, 1968): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts